Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 2,00 M
EBIT 2017 -11,9 M
Net income 2017 -9,44 M
Debt 2017 -
Yield 2017 -
Sales 2018 2,00 M
EBIT 2018 -9,63 M
Net income 2018 -7,26 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 6,15x
Capi. / Sales2018 6,15x
Capitalization 12,3 M
More Financials
Company
Cyclacel Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders.Its lead candidate, sapacitabine, oral nucleoside analogue prodrug that acts through a novel mechanism.It also develops... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
07/22 INSIDER TRADING ACTIVITY CYCLACEL PH : CYCC) – Major Shareholder Bought 85..
07/21 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Entry into a Material ..
07/21 CYCLACEL PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Mat..
07/21 Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and ..
07/20 CYCLACEL PHARMACEUTICALS : Announces Pricing of $13.2 Million Underwritten Publi..
07/20 CYCLACEL PHARMACEUTICALS INC : Today's Research Reports on Trending Tickers: Cyc..
07/19 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Financial Statements a..
07/19 CYCLACEL PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
07/19 Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering
06/30 CYCLACEL PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Hol..
More news
Sector news : Bio Therapeutic Drugs
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016 Midday Gainers / Losers
2016 Midday Gainers / Losers
2016 Cyclacel's lead product candidates show encouraging results in early-stage st..
2016 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
2016 Some Ideas For The Next Celator
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 7,00 $
Spread / Average Target 266%
EPS Revisions
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICALS INC8
AMGEN23.84%132 526
CELGENE CORPORATION19.08%107 551
GILEAD SCIENCES3.00%96 384
REGENERON PHARMACEUTICALS40.54%54 837
VERTEX PHARMACEUTICALS121.49%40 641